CooperVision launches Brilliant Futures™ Myopia Management Programme
featuring MiSight® 1 day contact lenses
Fareham, United Kingdom, 1 October 2020. CooperVision is pleased to announce the Brilliant Futures™ Myopia Management Programme, featuring the innovative MiSight® 1 day contact lens, is now available in the United Kingdom for the management of childhood myopia.
“The prevalence of childhood myopia in the UK has more than doubled over the past 50 years,” comments Mark Halling, Myopia Programme Manager, CooperVision. “Combined with this year’s lockdown measures, where many children have spent less time outdoors and more time learning via screen-based platforms, which may influence the development of myopia.,, It is vital to manage this progression early, and with urgency, to help protect future eye health. As global pioneers in this field we have developed Brilliant Futures™ to help eye care practitioners and parents slow myopic progression in children.”
Brilliant Futures™ seeks to introduce a new standard of care for children with myopia providing inclusive practice, child and parent support for compliance, satisfaction, clinical outcomes and long-term loyalty. Brilliant Futures™ is built around MiSight® 1 day contact lenses, with ActivControl™ Technology, which have been clinically proven to slow the progression of myopia in children as young as eight.*
The programme features:
- Professional Accreditation Programme delivered through CooperVision’s online Learning Academy. The programme equips practitioners to understand, initiate and develop a myopia management practice ahead of gaining access to Brilliant Futures™.
- In-Practice Tools helping practitioners identify those children most at risk of developing myopia and sophisticated communication tools to aid the introduction and subsequent commitment to intervention.
- Messaging Portal, currently in development, is an innovative text-based user support system linking patients directly to practitioners to gauge their lens-use experience and identify support needs.
Myopic progression has been linked to significant eye-health and sight-threatening conditions later in life such as cataracts, retinal detachment, glaucoma and myopic maculopathy. The risk of these conditions multiplies as a prescription gets stronger.,
This is echoed in the seminal World Health Organization (WHO) 2015 report that declared myopia is increasing globally at an alarming rate, leading to significant increases in the risks for vision impairment from pathologic conditions associated with high myopia.
According to recent studies, children in the UK are becoming myopic at a younger age, and the proportion of children with myopia has more than doubled over the last 50 years in those aged between 10–16 years.1
“Myopia management is about going beyond vision correction and providing longer-term benefits to young patients,” said Indie Grewal, Optometrist and President of the British Contact Lens Association (BCLA). “This innovative approach has the potential to revolutionise clinical outcomes and can allow us to change the trajectory of childhood myopia in practice. We now have an opportunity to tackle myopia head-on and ultimately help young patients see well into the future.”
CooperVision’s research into MiSight® 1 day’s effectiveness has been the longest continuous soft contact lens study for myopia management. The prospective, multi-centre, double-masked, randomised multi-year study enrolled 144 myopic children aged 8-12 years from Singapore, Canada, the United Kingdom and Portugal. Three-year peer-reviewed results published in Optometry and Vision Science in August 2019 indicated that use of MiSight® 1 day was shown to slow myopia progression by 59% on average as measured by mean cycloplegic spherical equivalent (SE) and 52% on average as measured by mean axial elongation of the eye.*
The trial has continued with highly encouraging results reported for years four and five, in which the original control group was refitted into MiSight® 1 day with some children wearing the contact lens in their late teens.
The MiSight® 1 day lens is already being successfully worn by thousands of myopic children in the UK and other parts of the world, including Australia, Canada and Spain.5 It has been recognised as one of the most innovative developments in eye health by the British Contact Lens Association and international industry media.
To learn more about the Brilliant Futures™ Myopia Management Programme, please visit coopervision.co.uk/practitioner/clinical-resources/myopia-in-children.
*Compared to a single vision 1 day lens over a 3-year period
CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About The Cooper Companies
The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of families with its diversified portfolio of products and services focusing on women’s health, fertility and diagnostics. Headquartered in Pleasanton, CA, Cooper has more than 11,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.
MEDIA CONTACT: Jamie Keenan, Health Unlimited
CONTACT DETAILS: Jamie.Keenan@unlimitedgroup.com
+44(0)7526 178 327
 McCullough S, et al. PLoS ONE. 2016;11: e0146332
 Wolffsohn J, et al. Cont Lens Anterior Eye. 2016;39:106–116
 WHO. The impact of increasing prevalence of myopia and high myopia. A Report of the Joint World Health Organisation (2015). Available at: www.who.int/blindness/causes/MyopiaReportforWeb.pdf. Accessed August 2020
 Gifford P & Gifford, K. Optom Vis Sci. 2016;93:336–343
 Chamberlain P, et al. Optom Vis Sci. 2019;96:556–567
 Tideman J, et al. JAMA Opthalmol. 2016;134:1355-1363
 Flitcroft, D. Prog Retin Eye Res. 2012;31(6):622-60
 Bourne R, et al. Lancet Glob Health. 2013;1(6):e339-49
 The Impact of Myopia and High Myopia. Report of the Joint World Health Organization-Brien Holden Vision Institute Global Scientific Meeting on Myopia. University of New South Wales, Sydney, Australia. 16-18 March 2015
 Chamberlain P, et al. Clinical evaluation of a dual-focus myopia control 1 day soft contact lens. 5-year results (2019 BCLA Clinical Conference & Exhibition).